摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2-{[(Tert-butoxy)carbonyl]amino}ethyl)-1,2-oxazole-3-carboxylicacid | 2287289-97-6

中文名称
——
中文别名
——
英文名称
5-(2-{[(Tert-butoxy)carbonyl]amino}ethyl)-1,2-oxazole-3-carboxylicacid
英文别名
5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,2-oxazole-3-carboxylic acid
5-(2-{[(Tert-butoxy)carbonyl]amino}ethyl)-1,2-oxazole-3-carboxylicacid化学式
CAS
2287289-97-6
化学式
C11H16N2O5
mdl
——
分子量
256.25
InChiKey
JENSYBUZSUONAU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    102
  • 氢给体数:
    2
  • 氢受体数:
    6

文献信息

  • [EN] HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLES UTILES EN TANT QU'INHIBITEURS DE KINASE RAF
    申请人:BIOGEN IDEC INC
    公开号:WO2010078408A1
    公开(公告)日:2010-07-08
    The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.
    本发明提供了一种化合物,其化学式为(I),可用作Raf蛋白激酶的抑制剂。本发明还提供了这些化合物的组合物,以及治疗Raf介导疾病的方法。
  • PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
    申请人:Sunesis Pharmaceuticals, Inc.
    公开号:EP2167489A2
    公开(公告)日:2010-03-31
  • HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    申请人:Sunesis Pharmaceuticals, Inc.
    公开号:EP2167497A2
    公开(公告)日:2010-03-31
  • HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    申请人:MILLENNIUM PHARMACEUTICALS, INC.
    公开号:EP2379513A1
    公开(公告)日:2011-10-26
  • [EN] HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF
    申请人:SUNESIS PHARMACEUTICALS INC
    公开号:WO2009006404A2
    公开(公告)日:2009-01-08
    The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Cy1 is an optionally substituted phenyl or an optionally substituted 5-6 membered saturated, partially unsaturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Cy2 is an optionally substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur; L1 is a direct bond of an optionally substituted, straight or branched C1-6 alkylene chain; L2 is a direct bond, or is an optionally substituted, straight or branched C1-6 alkylene chain wherein 1 or 2 methylene units of L2 are optionally and independently replaced by -O-, -S-, -N(R)-, -C(O)-, -C(O)N(R)-, -N(R)C(O)N(R)-, -N(R)C(O)-, -N(R)C(O)O-, -OC(O)N(R)-, -SO2-, -SO2N(R)-, -N(R)SO2-, -OC(O)-, -C(O)O-, or a 3-6 membered cycloalkylene; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group;
查看更多